Molgramostim
Showing 1 - 25 of 135
Autoimmune Pulmonary Alveolar Proteinosis Trial in Worldwide (Molgramostim, Placebo, PARI eFlow nebulizer system)
Completed
- Autoimmune Pulmonary Alveolar Proteinosis
- Molgramostim
- +2 more
-
Los Angeles, California
- +29 more
Dec 14, 2022
Mycobacterium Infections, Nontuberculous, Cystic Fibrosis (CF) Trial in United States (Molgramostim nebulizer solution, PARI
Terminated
- Mycobacterium Infections, Nontuberculous
- Cystic Fibrosis (CF)
- Molgramostim nebulizer solution
- PARI eFlow nebulizer system
-
Denver, Colorado
- +4 more
Oct 10, 2021
Venous Leg Ulcer Trial in Copenhagen (rhGM-CSF + hydrogel, Placebo hydrogel, Standard care)
Active, not recruiting
- Venous Leg Ulcer
- rhGM-CSF + hydrogel
- +2 more
-
Copenhagen, DenmarkDepartment of Dermatology and Copenhagen Wound Healing Center, B
Nov 16, 2022
Mycobacterium Infections, Nontuberculous Trial in Australia, United Kingdom (Inhaled molgramostim)
Completed
- Mycobacterium Infections, Nontuberculous
- Inhaled molgramostim
-
Concord, New South Wales, Australia
- +4 more
Mar 23, 2021
Severe Acute Respiratory Syndrome (SARS) Pneumonia, COVID-19 Pneumonia Trial in Germany (Molgramostim nebuliser solution,
Active, not recruiting
- Severe Acute Respiratory Syndrome (SARS) Pneumonia
- COVID-19 Pneumonia
- Molgramostim nebuliser solution
- Placebo nebuliser solution
-
Dresden, Germany
- +8 more
Jun 20, 2022
Autoimmune Pulmonary Alveolar Proteinosis Trial in Worldwide (Molgramostim, Placebo)
Recruiting
- Autoimmune Pulmonary Alveolar Proteinosis
- Molgramostim
- Placebo
-
Little Rock, Arkansas
- +54 more
Dec 14, 2022
Autoimmune Pulmonary Alveolar Proteinosis Trial in Worldwide (Molgramostim)
Completed
- Autoimmune Pulmonary Alveolar Proteinosis
- Molgramostim
-
Århus, Denmark
- +12 more
Feb 2, 2021
ARDS Trial in Germany (inhaled molgramostim (rhGM-CSF), inhaled )
Active, not recruiting
- ARDS
- inhaled molgramostim (rhGM-CSF)
- inhaled placebo
-
Würzburg, Baden-Würtemberg, Germany
- +6 more
Oct 27, 2021
Neuroblastoma Recurrent Trial in Hong Kong (Natural killer cell, Dinutuximab beta, Interleukin-2)
Recruiting
- Neuroblastoma Recurrent
- Natural killer cell
- +4 more
-
Hong Kong, Hong KongHong Kong Children's Hospital
Feb 22, 2023
Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Radiotherapy, PD-1/PD-L1 inhibitor, Granulocyte-macrophage
Recruiting
- Advanced Solid Tumor
- Refractory Tumor
- Radiotherapy
- +4 more
-
Suzhou, ChinaThe Second Affiliated Hospital of SchoowUniversity
Sep 14, 2023
Advanced Ovarian Cancer Trial in Seattle (AST-201, Paclitaxel, Carboplatin)
Not yet recruiting
- Advanced Ovarian Cancer
- AST-201
- +4 more
-
Seattle, WashingtonUniversity of Washington
Mar 20, 2023
HER2-positive Breast Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor Trial in Seattle
Active, not recruiting
- HER2-positive Breast Cancer
- +8 more
- pNGVL3-hICD vaccine
- +6 more
-
Seattle, WashingtonFred Hutchinson Cancer Research Center/University of Washington
Nov 1, 2022
Neuroblastoma Trial in Guangzhou (Naxitamab monotherapy, GM-CSF, Irinotecan)
Recruiting
- Neuroblastoma
- Naxitamab monotherapy
- +6 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Aug 31, 2023
Resectable Esophageal Cancer Trial in Hangzhou (iNeo-Vac-P01, GM-CSF)
Recruiting
- Resectable Esophageal Cancer
- iNeo-Vac-P01
- GM-CSF
-
Hangzhou, Zhejiang, ChinaThe Second Affiliated Hospital of Zhejiang University
Mar 23, 2022
Renal Cancer Trial in Boston (Dendritic Cell Tumor Fusion Vaccine, Granulocyte Macrophage Colony Stimulating Factor (GM-CSF))
Active, not recruiting
- Renal Cancer
- Dendritic Cell Tumor Fusion Vaccine
- Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
-
Boston, MassachusettsBeth Israel Deaconess Medical Center
Jan 2, 2023
Appendicitis Perforated Trial in Copenhagen, Herlev (Combination of fosfomycin, metronidazole and rhGM-CSF (administered
Completed
- Appendicitis Perforated
- Combination of fosfomycin, metronidazole and rhGM-CSF (administered together intraperitoneally) and three days of antibiotics p.o.
- Standard antibiotics intravenously
-
Copenhagen, Denmark
- +1 more
Oct 14, 2018
Hepatitis B, Chronic Trial in Beijing (Granulocyte Macrophage-colony Stimulating Factor, Entecavir)
Terminated
- Hepatitis B, Chronic
- Granulocyte Macrophage-colony Stimulating Factor
- Entecavir
-
Beijing, Beijing, China302 Military Hospital
Mar 9, 2022
Resectable Pancreatic Cancer Trial in Hangzhou (iNeo-Vac-P01, GM-CSF)
Recruiting
- Resectable Pancreatic Cancer
- iNeo-Vac-P01
- GM-CSF
-
Hangzhou, Zhejiang, ChinaZhejiang Provincial People's Hospital
Nov 15, 2021
Posterior Fossa Ependymoma (PFEPN) Trial in Aurora (Trastuzumab after SubQ GM-CSF, Trastuzumab in combination with SubQ GM-CSF)
Recruiting
- Posterior Fossa Ependymoma (PFEPN)
- Trastuzumab after SubQ GM-CSF
- Trastuzumab in combination with SubQ GM-CSF
-
Aurora, ColoradoChildren's Hospital Colorado
Dec 2, 2021
Pediatric Sepsis-induced MODS Trial in United States (GM-CSF)
Active, not recruiting
- Pediatric Sepsis-induced MODS
-
Los Angeles, California
- +7 more
Feb 24, 2022
Advanced Malignant Solid Tumor Trial in Hangzhou (iNeo-Vac-P01, GM-CSF)
Active, not recruiting
- Advanced Malignant Solid Tumor
- iNeo-Vac-P01
- GM-CSF
-
Hangzhou, Zhejiang, ChinaSir Run Run Shaw Hospital
Nov 15, 2021
Pancreatic Cancer, Pancreatic Carcinoma Trial in Hangzhou (iNeo-Vac-P01, GM-CSF)
Completed
- Pancreatic Cancer
- Pancreatic Carcinoma
- iNeo-Vac-P01
- GM-CSF
-
Hangzhou, Zhejiang, ChinaZhejiang Provincial People's Hospital
Nov 15, 2021
Down Syndrome Trial in Aurora (Sargramostim for Injection, Saline Placebo)
Not yet recruiting
- Down Syndrome
- Sargramostim for Injection
- Saline Placebo
-
Aurora, ColoradoUniversity of Colorado Anschutz Medical Campus
Jul 28, 2022
Triple-Negative Breast Cancer Trial in Worldwide (Tiragolumab, Atezolizumab, Nab-paclitaxel)
Active, not recruiting
- Triple-Negative Breast Cancer
- Tiragolumab
- +7 more
-
Birmingham, Alabama
- +23 more
Jan 19, 2023